Lymphoma - Biotech, Pharma and Life Science Channel
Lymphoma is a cancer of the lymph nodes; classified as Hodgkin or non-Hodgkin lymphoma.
Malignancy varies, and the prognosis can be from a few months to many years. Symptoms include enlarged lymph nodes, weight loss, fever and sweating.
Treatment involves chemotherapy, and possibly radiotherapy if the disease is very localized. Bone marrow transplants are also a possibility for non-Hodgkin lymphomas that have not responded to other treatments.
Source; Adapted from Oxford Concise Medical Dictionary
Add the Lymphoma News Channel to your RSS reader;
News Articles
WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6 million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene...
Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-l...
Stanton Optical Gives Back to the Community Through Local and National Corporate Donations
PALM SPRINGS, Fla., May 17, 2013 /PRNewswire-iReach/ -- Stanton Optical is especially proud of their community involvement program with the support of both non-profit charity organizations and humanit...
Infinity Announces Clinical Data to Be Presented at ASCO and ICML
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Phase 1 clinical data for IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K...
-- Regimen Achieves 97 Percent Overall Response Rate with Estimated Progression-Free Survival at 24 Months of 93 Percent -- -- Results from Study 101-08 and Other Idelali...
NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented a...
RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the...
sBLA Supports Use of ADCETRIS for Retreatment and Extended Duration of Therapy in Relapsed Hodgkin Lymphoma and Systemic ALCL Seattle Genetics, Inc. (NASDAQ:SGEN) announced to...
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma
MorphoSys AG / MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for...
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma
MARTINSRIED / MUNCHEN, GERMANY -- (Marketwired) -- 05/13/13 -- MorphoSys AG / MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma . Processed and transmitted by...
Events
None
Companies
Eutropics Pharmaceuticals Inc.
Eutropics is addressing the need for improving the treatment of aggressive forms of leukemia, myeloma, lymphoma, and other cancers. The company is developing a novel diagnostic te...
Nimbus Discovery is applying advances in computer-based drug discovery to develop new medicines against important drug targets and thereby unlock fundamental biological pathways....
The Leukemia & Lymphoma Society and Reliant Energy
The Leukemia & Lymphoma Society ® (LLS) is the worldâs largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkinâ...
Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early st...
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatme...
Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, âsoft-drugâ HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...
Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collabor...
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currentl...
Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to si...
Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companyâs pipel...
Clinical Trials
Background: - Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather...
Stem Cell Collection With Ofatumumab
The goal of this clinical research study is to learn if it is possible to collect stem cells after ofatumumab and chemotherapy treatment. This study will also evaluate side-effects, number...
RATIONALE: Herpesvirus is found in the cancer cells of patients with primary effusion lymphoma. Antiviral drugs, such as zidovudine and valganciclovir, may be able to act against the herpe...
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and he...
RATIONALE: Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinos...
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rituximab has been demonstrated to sensitize drug-resistant NHL cells to the cytotoxic actions of several chemotherapy agents by enhancing sensitivity of tumor cells to chemotherapy-induce...
Aim of the study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to C...
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Number of elderly people over 70 is increasing in France. In 2002, in the south-west, 273,741 of them were over 75 years, i.e. 9.2% of Aquitaine population. Incidence of cancer in this old...
Patients with acute lymphoblastic leukaemia or very aggressive lymphoma and documented isolated CNS relapse or CNS relapse combined with other relapse sites should receive therapy with int...
In this study the efficacy and tolerability of two approaches to treat and prevent hyperuricemia is tested in patients with acute lymphoblastic leukemia or high-grade lymphoma with high ri...
PubMed Articles
Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon.
Mucosa-associated lymphoid tissue (MALT)-type lymphomas most commonly occur in the stomach and have been associated with Helicobacter pylori infection. However, MALT-type lymphoma of the colon is a ra...
8p21.3 deletion was recently characterized in B cell lymphoma suggesting that TRAIL-R1 and TRAIL-R2 may be the target of the deletion and act as dosage-dependent tumor suppressor genes. As multiple my...
Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase represents a potential therapeutic target. Specially, a variety of alterations in the ALK gene including mutations, overexpression, amplif...
Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteri...
Follicular Lymphoma Presenting as an Isolated Colonic Polyp.
ABSTRACT We have analyzed the immunohistochemical expression of a wide range of molecules, along with the proliferation rate separately in the proliferation centers (PCs) and in the rest of tumor area...
SMAC mimetic potentiates tumor susceptibility towards natural killer cell-mediated killing.
Abstract Resistance to apoptosis is a hallmark of cancer and represents an important mechanism how tumor cells resist immune cell destruction. Mitochondria are the central regulators of the apoptotic...
The Importance of Notch Signalling in Peripheral T-Cell Lymphomas.
Abstract Peripheral T-cell lymphomas (PTL) represent an area of high medical need. Previously, we demonstrated high expression of Notch, a known oncogene, in primary cutaneous anaplastic large cell ly...
Activated B-cell lymphoma (ABC), a subgroup of Diffuse Large B-cell lymphoma (DLBCL) has a worse survival after upfront chemotherapy and is characterized by constitutive activation of the anti-apoptot...
Videos
Laura's Hodgkin's Lymphoma Story
Hello :) on Christmas Eve 2010 I was diagnosed with stage 4 Hodgkin's Lymphoma. This is a video telling you the story of when I had my first symptoms, having...
Medical and Biotech [MESH] Definitions
Candida Tropicalis
A species of MITOSPORIC FUNGI that is a major cause of SEPTICEMIA and disseminated CANDIDIASIS, especially in patients with LYMPHOMA; LEUKEMIA; and DIABETES MELLITUS. It is also found as part of the normal human mucocutaneous flora.
Oncogene Protein V-cbl
An oncoprotein from the Cas NS-1 murine retrovirus that induces pre- B-CELL LYMPHOMA and MYELOID LEUKEMIAS. v-cbl protein is a tyrosine-phosphorylated, truncated form of its cellular homologue, PROTO-ONCOGENE PROTEIN C-CBL.
Oncogene Protein V-akt
A viral oncoprotein originally isolated from a murine T CELL LYMPHOMA infected with the acutely transforming retrovirus AKT8. v-akt protein is the viral homologue of PROTO-ONCOGENE PROTEINS C-AKT.
Proto-oncogene Proteins C-bcl-6
A DNA-binding protein that represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.
Precursor Cell Lymphoblastic Leukemia-lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
